studies

breast cancer - HER2-positive, lapatinib plus trastuzumab vs. trastuzumab based treatment, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS) (extension)detailed resultsALTTO (T plus L vs T), 2020 0.86 [0.70; 1.06] 0.86[0.70; 1.06]ALTTO (T plus L vs T), 202010%4,190NAnot evaluable RFS/DFSdetailed resultsALTTO (T plus L vs T), 2020 0.84 [0.70; 1.01] 0.84[0.70; 1.01]ALTTO (T plus L vs T), 202010%4,190NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-06-08 08:17 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 336,147,145,355,337,146,317 - treatments: 1302